Evidence map›Paper›PMID 38283131›Full record

ArticleMedicine international

Single metachronous bone metastasis following rectal adenocarcinoma: A case report.

Belén Matías-García, Fernando Mendoza-Moreno, Manuel Díez-Alonso, Enrique Ovejero-Merino, Cristina Vera-Mansilla, Alma Blázquez-Martín, Ana Quiroga-Valcárcel, Rubén Jiménez-Martín, Rebeca D'amico, Inmaculada Lasa-Unzúe and 1 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Cancer metastasisFrontiers in bioengineering and biotechnology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Belén Matías-GarcíaDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Fernando Mendoza-MorenoDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Manuel Díez-AlonsoDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Enrique Ovejero-MerinoDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Cristina Vera-MansillaDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Alma Blázquez-MartínDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Ana Quiroga-ValcárcelDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Rubén Jiménez-MartínDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Rebeca D'amicoDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Inmaculada Lasa-UnzúeDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Alberto Gutiérrez-CalvoDepartment of General and Digestive Surgery, Príncipe of Asturias Teaching Hospital, Alcalá de Henares, 28805 Madrid, Spain.
Hospital Universitario Príncipe de Asturias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) ranks as the third leading cause of cancer-related mortality in developed countries. While its incidence in early stages has increased due to screening programs, a significant number of patients experience the development of metastases either at the time of diagnosis or during follow-ups. Unlike certain other types of cancer, such as breast, prostate, or lung cancer, where bone tissue is a common site for secondary dissemination, CRC primarily spreads to the lymph nodes, liver and lungs. The occurrence of bone metastases from CRC is rare and usually coincides with tumor involvement in other locations. Risk factors for bone metastases include the location of the primary tumor, the age of the patients, KRAS mutations and the degree of tumor differentiation. Unlike metastases to the liver and lungs, bone metastases tend to be symptomatic, affecting the patient's quality of life and resulting in a poorer prognosis with shorter survival rates. The approach to patient management needs to be personalized. The present study describes the of a patient who underwent surgery for stage IV rectal adenocarcinoma and later developed a metastasis in the costal wall 79 months post-intervention, with no evidence of recurrence at other sites.

Indexed as

bone metastasescolorectal cancerKRASliverlungsurvival

Identifiers

PMID38283131
PMCPMC10811448
OpenAlexW4390544695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.